Skip to main content

Endometrium

Updated May 2018

FIGO Staging

Distribution of patients and approximate Five Year Survival by Surgical Stage/Sub-stage [REVISED FIGO STAGE 2009]

(corrected to exclude death from intercurrent disease)

FIGO stage

Substage

Definition

Proportion of all patients

5-year overall survival

I

Tumour confined to corpus uteri

 

 

 

IA

Tumour limited to endometrium or invades less than one half of the myometrium

56%

90%

IB

Tumour invades one half or more of the myometrium

20%

81%

II

 

Tumour invades stromal connective tissue of the cervix but does not extend beyond uterus

7%

67%

III

Local and/or regional spread

 

 

 

IIIA

Tumour involves serosa and/or adnexae (direct extension or metastases)

8%

60%

IIIB

Vaginal involvement (direct extension or metastasis) or parametrial involvement

2%

41%

IIIC

Metastases to pelvic and/or para-aortic lymph nodes

4%

32%

IIIC1

Regional lymph node metastases to pelvic lymph nodes

 

 

IIIC2

Regional lymph node metastasis to para-aortic lymph nodes, with or without positive pelvic lymph nodes

 

 

IV

Tumour invades bladder mucosa and/or bowel mucosa, and/or distant metastases

 

 

 

IVA

Tumour invades bladder mucosa and/or bowel mucosa (bullous edema is not sufficient to classify a tumour as T4)

1%

20%

IVB

Distant metastases (includes metastases to inguinal lymph nodes, intraperitoneal disease, or lung, liver, or bone metastases)

3%

5%

Changes from previous staging system:

  1. FIGO no longer includes Stage 0 (carcinoma in situ)
  2. Stage IA/IB combined into Stage IA; Stage IB now includes deep myometrial invasion (previous Stage IC)
  3. Endocervical glandular involvement only should be classified as Stage I – it is no longer stage II
  4. Peritoneal cytology no longer included in staging system
  5. Stage IIIC subdivided into pelvic nodes alone (Stage IIIC1) or involved para-aortics (Stage IIIC2)

NB: Omentum or peritoneal disease = Stage IVB

It should be noted that these figures are approximations of five-year survival data collected from large numbers of patients within a given stage (FIGO data). Caution should be used in attempting to use these data to assign prognosis in an individual case as outcomes within these substages will worsen depending on grade and histotype (e.g., papillary serous and MMMT).

SOURCE: Endometrium ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer. All Rights Reserved.

    Copyright © 2021 Provincial Health Services Authority